Tagged with Fact

regulator The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming a PIC/s member, and the introduction of several changes designed to accelerate timelines for GMP certifications and marketing authorizations.   You began your TITCK…

locals The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than twenty countries across the EU, CIS, GCC and MENA regions. As a company working on bringing biotech production to Turkey,…

locals Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please introduce Keymen and explain the company in the broader context of the Turkish pharmaceutical market. Keymen is a family company…

locals Imuneks is currently operating in the OTC market, but with three supergeneric products ready to market on the RX side, the firm has the potential to soon become one of Turkey’s most innovative pharmaceutical players.  To begin, could you please introduce yourself and Imuneks to our readers around the world?…

Generics The general manager of Novagen Pharma reveals how they are the second largest supplier of ARVs within the private South African market, how there is much room for the generics market to grow given that it currently represents just one third of the total private market and how as the…

Recordati Recordati’s South East regional VP, based in Istanbul, discusses Recordati Turkey’s key role as a manufacturing hub for Recordati, the importance of the Turkish market (fourth largest globally for the group) to the global organization, and current initiative to increase investment and develop a new manufacturing facility in the country.…

local The owner of an indigenous producer and contract manufacturer explains the plethora of new opportunities unfolding for customized industrial batch manufacturing and the impact that EU accession had on the local pharma manufacturing industry. How has domestic pharmaceutical production evolved in Romania? One of the landmark moments for Romanian pharmaceutical production…

Allergan Frank Rodríguez, General Manager for Allergan Operations in Puerto Rico, discusses cost-competitiveness at his plants in Fajardo and Manatí, which manufacture hormones and solid dosage forms respectively. He also outlines the company’s recent $48 million investment in expanding these facilities. What were the initial priorities you set? When I arrived…

Association Promoting the manufacturing industry of Puerto Rico is a key priority for Carlos Rivera, president of the Puerto Rico Manufacturers Association (PRMA). He discusses the strategies behind working with Washington and countries abroad to make the island a hub for business in the Caribbean. What are the main priorities of…

Merck Andrew Wirths arrived to Puerto Rico in 2013 to run Merck’s manufacturing operations on the island. He discusses how dynamic changes within the industry is impacting their competitive nature and recent investments that Merck is making in Puerto Rico’s facilities, which represent a key part of the company’s commercialization process.…

association Jaime García, executive director of the Puerto Rico Manufacturers Association, provides an overview of the current state of the industry in Puerto Rico today. You were named executive director of PRMA in January 2013, following an illustrious career in many government positions and associations. What was your initial mandate? My…

local company Turkey’s leading pharmaceutical company is in the process of developing production facilities abroad, and it has just begun construction of a USD 100 million biotech facility; CEO Süha Taşpolatoğlu believes that these two steps will help bring the company closer to its aspiration of becoming a pharmaceutical player on the…